Treatment for tobacco dependence: a potential application for stratified medicine?

被引:0
|
作者
Brock, Alistair J. [1 ,2 ]
Takeda, Andrea [1 ]
Brennan, Caroline [2 ]
Walton, Robert T. [1 ]
机构
[1] Univ London, Ctr Primary Care & Publ Hlth, Barts & London Med Sch, Blizard Inst, London WC1E 7HU, England
[2] Univ London, Sch Biol & Chem Sci, London WC1E 7HU, England
基金
英国医学研究理事会;
关键词
addiction; GWAS; nicotine; personalized medicine; pharmacogenetics; stratified medicine; tobacco; NICOTINE REPLACEMENT THERAPY; CATECHOL-O-METHYLTRANSFERASE; SMOKING-CESSATION; GENETIC-VARIATION; TRANSDERMAL NICOTINE; FRAMEWORK CONVENTION; CIGARETTE-SMOKING; CYP2B6; GENOTYPE; RECEPTOR DRD2; LUNG-CANCER;
D O I
10.2217/PME.11.60
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tobacco addiction is a leading preventable cause of death worldwide and places a heavy social and financial burden on society. Therefore, ways of helping people to overcome nicotine dependence are a key element of strategies aimed at improving public health. Current treatments are only partially effective and there is a need to develop more efficient approaches to help smokers to stop. There exists a substantial genetic variability in smoking behavior and the likelihood of cessation - tailoring treatment according to an individual's genetic profile is now technologically feasible and could lead to more successful cessation attempts. Here we review studies of the genetic effects on smoking cessation in randomized controlled trials of pharmacological therapy and discuss the potential value of a personalized approach to help people stop smoking.
引用
收藏
页码:571 / 579
页数:9
相关论文
共 50 条
  • [41] Critical appraisal of tobacco dependence treatment guidelines
    Maguy Saffouh El Hajj
    Myriam Jaam
    Saba Abdal Salam Sheikh Ali
    Rana Saleh
    Ahmed Awaisu
    Bridget Paravattil
    Kyle John Wilby
    International Journal of Clinical Pharmacy, 2021, 43 : 85 - 100
  • [42] Mobile Applications for the Treatment of Tobacco Use and Dependence
    Roger Vilardaga
    Elisabet Casellas-Pujol
    Joseph F. McClernon
    Kathleen A. Garrison
    Current Addiction Reports, 2019, 6 : 86 - 97
  • [43] ACETYLCHOLINESTERASE-INHIBITORS IN THE TREATMENT OF TOBACCO DEPENDENCE
    Diehl, A.
    EUROPEAN PSYCHIATRY, 2009, 24
  • [44] Time to rethink tobacco dependence treatment in Australia
    Buchanan, Tanya
    White, Sarah L.
    Marshall, Henry
    Carson-Chahhoud, Kristin V.
    Magee, Christopher A.
    Kelly, Peter J.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH, 2021, 45 (06) : 538 - 540
  • [45] Concurrent alcohol and tobacco dependence - Mechanisms and treatment
    Drobes, DJ
    ALCOHOL RESEARCH & HEALTH, 2002, 26 (02) : 136 - 142
  • [46] Role of Primary Care Providers in Tobacco Cessation, Tobacco Dependence Treatment
    Ruhil, Rohini
    INDIAN JOURNAL OF COMMUNITY HEALTH, 2015, 27 (01) : 8 - 12
  • [47] Bupropion sustained release for treatment of tobacco dependence
    Hays, JT
    Ebbert, JO
    MAYO CLINIC PROCEEDINGS, 2003, 78 (08) : 1020 - 1024
  • [48] Treatment of tobacco dependence: current state of the art
    Kathuria, Hasmeena
    Leone, Frank T.
    Neptune, Enid R.
    CURRENT OPINION IN PULMONARY MEDICINE, 2018, 24 (04) : 327 - 334
  • [49] Time to take tobacco dependence treatment seriously
    Raw, Martin
    Mackay, Judith
    Reddy, Srinath
    LANCET, 2016, 387 (10017): : 412 - 413
  • [50] TOBACCO DEPENDENCE - PSYCHOLOGY, BIOLOGY, AND TREATMENT STRATEGIES
    MANN, LS
    JOHNSON, RW
    LEVINE, DJ
    PSYCHOSOMATICS, 1986, 27 (10) : 713 - 718